P114 Filgotinib in ulcerative colitis: early real-world experience in Southampton
Notice bibliographique
Résumé
<h3>Introduction</h3> Filgotinib was licensed for use in ulcerative colitis in the UK in January 2022 and NICE approved in June 2022. We reviewed our patients treated with filgotinib following the additional measures recommended by the EMA to identify those at increased risk of side effects with JAK inhibitors. The position of filgotinib in therapeutic pathways and the ideal sequence of medications needs defining. This is a description of the real-world experience of its effectiveness and patient reported outcomes in one IBD tertiary referral centre. <h3>Methods</h3> Patients, as part of clinical care, had blood safety monitoring, adverse event recording and effectiveness measured using faecal calprotectin (FC), SCCAI and IBD-Control. Endoscopy data, where available, was collected. A retrospective observational analysis was conducted. <h3>Results</h3> All 31 patients initiated on filgotinib are included in this analysis. The mean age was 43 (SD ± 16) years, 17 were male and median disease duration was 3 (IQR 2–10) years. Disease extent (as per Montreal classification) is: E1: 3, E2: 8 and E3: 20. Four patients had previously been exposed to tofacitinib, 21 to anti-TNFα agents, 16 to vedolizumab and 7 to ustekinumab. 6 patients had not received any prior cytokine modulator drugs. 5 patients had at least one risk factor included in the EMA warning. At baseline median FC was 1037, 22 patients had SCCAI ≥6 and 11 patients were taking oral corticosteroids. of 20 patients who had endoscopic assessment at baseline, 17 had a Mayo score of ≥2. Persistence at 120 days was 65% (figure 1A). Four patients had primary non-response, two secondary loss of response and two patients stopped due to adverse events. of the 10 patients who remained on treatment and received follow up (mean 103 days), all had a clinically significant reduction in SCCAI score of ≥3 (figure 1B) and 9 had an improvement in their IBD-Control-8 subscore. 13 patients are awaiting follow-up but continue on the medication. Filgotinib was generally well tolerated, other than minor side effects including headache, pruritis and nausea. There were no venous thromboembolisms reported. Two patients underwent colectomies, both patients had prior exposure to all classes of approved biological medicines. No other serious adverse events were reported. <h3>Conclusions</h3> In this small group, that included a proportion of complex patients, filgotinib appears to be efficacious and well tolerated.
Récupéré en direct depuis OpenAlex et désinversé. Les résumés ne sont pas conservés dans cette base de données : les index inversés représentent 8,6 Go des 9,3 Go de texte de la base, et le serveur dispose de 13 Go libres.
Comment cette classification a été obtenuedéplier
Prédiction distillée sur la base complète
Imitation des enseignantsNi prévalence calibrée, ni vérité terrain. Validation humaine à venir. Apprise à partir de 10 348 étiquettes directes de Codex et de 10 348 étiquettes directes de Gemma. Le mode candidate est l'union des têtes enseignantes seuillées; le consensus est leur intersection. Ces sorties portent le statut machine_predicted_unvalidated et ne sont ni des étiquettes humaines ni des étiquettes directes de modèles de pointe.
Scores Codex et Gemma par catégorie
| Catégorie | Codex | Gemma |
|---|---|---|
| Métarecherche | 0,000 | 0,000 |
| Méta-épidémiologie (sens strict) | 0,000 | 0,000 |
| Méta-épidémiologie (sens large) | 0,000 | 0,000 |
| Bibliométrie | 0,000 | 0,000 |
| Études des sciences et des technologies | 0,000 | 0,000 |
| Communication savante | 0,000 | 0,000 |
| Science ouverte | 0,000 | 0,000 |
| Intégrité de la recherche | 0,000 | 0,000 |
| Charge utile insuffisante (le modèle a refusé de juger) | 0,000 | 0,000 |
Scores machine (provisoires)
Les deux têtes enseignantes du modèle étudiant, lues sur ce travail. Un score ordonne la base pour la relecture; il n'affirme jamais une catégorie, et le statut de validation accompagne chaque rangée tel quel.
Scores de référence d'un modèle non mature (critères de maturité non atteints, 7 itérations). Un score ordonne; il n'affirme jamais une catégorie.
score_only:v0-immature-baseline · tel quel depuis la passe de notation : score_only signifie que le nombre peut ordonner les travaux, et qu'aucune étiquette de catégorie n'en découleClassification
machine, non validéePrédiction automatique; un appel candidat d’une seule tête enseignante, pas un consensus.
Le détail, modèle par modèle et score par score, se trouve en fin de page sous « Comment cette classification a été obtenue ».